Form PTO-1449 (Rev.)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. C015043/0174944	SERIAL NO. Not Yet Assigned
INFORMATION	ON DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Harold M. Bates	
(Us	e several sheets if necessary)	FILING DATE Filed Concurrently herewith	GROUP Not Yet Assigned

Examiner Initial	Cite No.	U.S. Patent Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
		5,024,829	6/1991	Berger et al.			
		5,026,537	6/1991	Daddona et al.			
		5,046,499	9/1991	Berger	İ		
		5,120,834	6/1992	Gargan et al.			
		5,196,324	3/1993	Bumol et al.			
		5,223,410	6/1993	Gargan et al.		,	
		5,362,649	11/1994	Schwertner			
		5,380,667	1/1995	Schwertner			
		5,396,886	3/1995	Cuypers			
		5,453,359	9/1995	Gargan et al.			
		5,487,892	1/1996	Gargan			
		5,597,726	1/1997	Bumol et al.			
		5,604,105	2/1997	Jackowski			
		5,658,729	8/1997	Hayden et al.			
		5,690,103	11/1997	Groth et al.			
		5,710,008	1/1998	Jackowski			
		5,731,208	3/1998	Henicke			
		5,756,067	5/1998	Redgrave et al.			
		6,040,147	3/2000	Ridker et al.			
		6,309,888	10/2001	Holvoet			
		2003/0100486	5/2003	Ridker			
		2003/0152566	8/2003	Schonbeck et al.			
					- 1		

EXAMINE

/Christine Foster/ (06/10/2009)

DATE CONSIDERED

06/10/2009

Form PTO-1449 (Rev.)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. C015043/0174944	SERIAL NO. NotYet Assigned
INFORMATIO	ON DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Harold M. Bates	
(Us	e several sheets if necessary)	FILING DATE Filed Concurrently Herewith	GROUP Not Yet Assigned

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Trans	slation
	EP 0 327 418 A1	8/1989	EPO			Yes	No
	EP 0 433 088 B1	6/1997	EPO				
	EP 0 484 863 A1	5/1992	EPO				
	WO 94/23302	10/1994	PCT				
	WO 98/59248	12/1998	PCT				
	WO 00/14548	3/2000	PCT				
	Kokai 8-304395	11/1996	JP			х	
	Kokai 9-5323	10/1997	JP			х	
100							
					-		
			<u></u>				
EXAMINER	/Christine Foste	r/ (06/10/200	DATE CONSIDER	ED 06/	10/2009		

Form (Rev.	PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. C015043/0174944	SERIAL NO. No Yet Assigned
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Harold M. Bates	
	(Use several sheets if necessary)	FILING DATE Filed Concurrently Herewith	GROUP Not Yet Assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Ladenson JH, Jaffe AS. "	avila-Roman VG, Delmez JA, Apple FS, Cardiac Troponin I. A Marker With iac Injury," Circulation 1993;
American Biogenetic Scient (1995).	ces Inc. 1995 Annual Report. 24 pages
	ces. Focus on Diagnostic Tests: A ted Full Report. 33 pages. Paisley 3, 1996).
	ces, Inc., "Renal dialysis joint ican Biogenetic Sciences, Inc. and News Release (9/26/96)
	ces, Inc. Jesup & Lamont Securities ommendation dated March 28, 1996" (12
Cannon CP, Fischer GA, Fu Braunwald E. "Cardiac-Sp The Risk Of Mortality In	Thompson B, Schactman M, McCabe CH, mg AY, Thompson C, Wybenga D, ecific Troponin I Levels To Predict Patients With Acute Coronary d. 1996; 335(18): 1342-1349.
	ut of Web Site Home page and "Technology Platform" s. 17 pages (printed June 8, 1998).
Lipoprotein Is Taken Up B	nolipase D-Modified Low Density y Macrophages At Increased Rate. A tidic Acid." <i>J. Clin. Invest</i> . 1993;
	"The Role Of Oxidized Lipoproteins adical Biology & Medicine 1996;
/Christine Foster/ (06/10/2009)	DATE CONSIDERED 06/10/2009

Form PTO-1449 (Rev.)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. C015043/0174944	SERIAL NO. No Yet Assigned
INFORMATI	ON DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Harold M. Bates	
(Us	se several sheets if necessary)	FILING DATE Filed Concurrently Herewith	GROUP Not Yet Assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Proti- Oxida Watau Novei Brod The Brown Macri Athei Cart "Chri Smoo Surg Chap Infa: 393- Chen PD. Impa Vitr Chin Deri Inve Cock from Cris "Ant. Acce	OTTER DOCUMENTS (including /	Rumor, Title, Date, Periment Pages, Etc.)
The Brown Macro Ather Cart "Chro Smoo Surg Chap Infa: 393- Chen PD. Impa Vitr Chin Deri Inve Cock from Crisp "Ant Acce Dise Cart Chap Cart Cart Cart Cart Cart Cart Cart Cart	tein Recognized By A Mo datively Modified LDL I	G, Chait A. "Direct Evidence For A moclonal Antibody Against n Atherosclerotic Lesions From A bbbit." Am. J. Pathol. 1989
Macra Atherman Atherman Atherman Atherman Atherman Atherman Atherman Atherman Atherman Acception Atherman Acception Caristan C	dy, JE. "Hunt For Hear New York Times. 3 pag	t Disease Tracks A New Suspect." ges (Jan. 6, 2004).
"Chrismos Surg Chap Infa: 393-: Chen PD. Impa Vitr Chin Deri Inve. Cock from Crisman Crisman Chen Crisman Crisman Chen Crisman Crisma Crisman Crisman Crisman Crisman Crisman Crisman Crisman Crisman	rophage: Implications F	Lipoprotein Metabolism In The For Cholesterol Deposition In Review Biochem. 1983; 52: 223-261.
Infa 393- Chen PD. Impa Vitr Chin Deri Inve. Cock from Cris "Ant Acce	ronic Exposure To Cyclo	lmann C, Cambron H, Buluran J. sporin Affects Endothelial And 'n The Rat Aorta." Ann. Thorac.
PD. Impa Vitr Chin Deri Inve Cock from Cris "Ant Acce		We proceed When A Myocardial Acta Clinica Belgica 1984; 39(6):
Deri Inve	"Basic Fibroblast Gro	echer D, Luo S, Gotto Jr. AM, Henry with Factor Reverses Atherosclerotic rry Angiogenesis-Like Responses In 1995; 116: 261-268.
from Cris		BB. "Inactivation Of Endothelial Oxidized Lipoproteins." J. Clin.
"Ant Acce Dise	kcroft DW, Gault MH. " m serum creatinine." Ne	Prediction of creatinine clearance
	elerating Factor In Tra ease?" J. Heart Lung T	n, Barbir M, Yacoub MH. s After Heart Transplantation: The nsplant-Associated Coronary Artery Yransplant. 1994; 13(1, Part 1): 81-
examiner /Christin	tine Foster/ (06/10/2009)	DATE CONSIDERED 06/10/2009

Form PTO-1449 (Rev.)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. C015043/0174944	SERIAL NO. Nöfyet Assigned
INFORMATI	ON DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Harold M. Bates	
(Us	se several sheets if necessary)	FILING DATE Filed Concurrently Herewith	GROUP Not Yet Assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Declerck PJ, Mombaerts P, Holvoet P, De Mol M, Collen D. "Fibrinolytic Response And Fibrin Fragment D-Dimer Levels In Patients With Deep Vein Thrombosis." Thromb. Haemost. 1987; 58(4): 1024-1029.
	Degoulet P, Legrain M, Reach I, Aime F, Devries C, Rojas P, Jacobs C. "Mortality Risk Factors In Patients Treated By Chronic Hemodialysis." Nephron 1982; 31: 103-110.
	Esterbauer H, Jurgens G, Quehenberger Q, Koller E. "Autooxidation Of Human Low Density Lipoprotein: Loss Of Polyumsaturated Fatty Acids And Vitamin E And Generation Of Aldehydes." J. Lipid Res. 1987; 28: 495-509.
	Farber HW, Barnett HF. "Differences In Prostaglandin Metabolism In Cultured Aortic And Pulmonary Arterial Endothelial Cells Exposed To Acute And Chronic Hypoxia." Circ. Res. 1991; 68(5): 1446-1457.
	Fogelman MA, Shechter I, Seager J, Hokom M, Child JS, Edwards PA. "Malondialdehyde Alteration Of Low Density Lipoproteins Leads To Cholesteryl Ester Accumulation In Human Monocyte-Macrophages." Proc. Natl. Acad. Sci. USA 1980; 77(4): 2214-2218.
	Folcik VA, Nivar-Aristy RA, Krajewski LP, Cathcart MK. "Lipoxygenase Contributes To The Oxidation Of Lipids In Human Atherosclerotic Plaques." J. Clin. Invest. 1995; 96: 504-510.
	Friedman JA, Dwyer JT. "Hyperhomocysteinemia As A Risk Factor For Cardiovascular Disease In Patients Undergoing Hemodialysis." Nutr. Rev. 1995; 53(7): 197-201
	Galle J, Bengen J, Schollmeyer P, Wanner C. "Oxidized Lipoprotein(A) Inhibits Endothelium-Dependent Dilation: Prevention By High Density Lipoprotein." Eur. J. Pharmacol. 1994; 265: 111-115.
EXAMINER /(Christine Foster/ (06/10/2009) DATE CONSIDERED 06/10/2009
	tation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and ic copy of this form with next communication to applicant.

Form PTO-1449 (Rev.)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. C015043/0174944	SERIAL NO. No.Yet Assigned
INFORMATI	ON DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Harold M. Bates	-
(Us	se several sheets if necessary)	FILING DATE Filed Concurrently Herewith	GROUP Not Yet Assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Nanner C. "Cyclosporin And Oxidized Synergistically Potentiate ace Of The Endothelium." Eur. Heart J. 17. The Monocyte In Atherogenesis. I. Monocytes Into Foam Cells In Fatty 1981; 103(2): 181-190. CE, Starnes VA, Oyer PE, Stinson EB, rus Infection Is Associated With
Monocytes Into Foam Cells In Fatty 1981; 103(2): 181-190. . CE, Starnes VA, Oyer PE, Stinson EB,
on And Atherosclerosis." J. Am. Med. 11-3566.
1, Edwards PA. "Specificity Of tion Of Malondialdehyde-Modified Low roc. Natl. Acad. Sci USA. 1982; 79:
gelman AM. "Role Of Lysines In Modified Low Density Lipoproteins oor Of Human Monocyte Macrophages." J. : 11305-11311.
eschen C, Kreymann G, Berger J, Room Triage Of Patients With Acute upid Testing For Cardiac Troponin T Or Med. 1997; 337(23): 1648-1653.
eschen C, Kreymann G, Berger J, koom Triage Of Patients With Acute ppid Testing For Cardiac Troponin T Or Med. 1997, 337(23): 1648-1653. and authors' reply, published in N.

 ceint date: (02/12/2004	1	O SPREETS 2008 L8 GALL: 1
Form PTO-1449 (Rev.)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. C015043/0174944	SERIAL NO. No Yet Assigned
INFORM	IATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Harold M. Bates	
	(Use several sheets if necessary)	FILING DATE Filed Concurrently Herewith	GROUP Not Yet Assigned
	OTHER DOCUMENTS (Including A	uthor, Title, Date, Pertinent Pages, Etc.)	
	Hammer A, Kager G, Dohr G, "Generation, Characterizati Of Monoclonal Antibodies S Modified ApoB-Containing St Arterioscler. Thromb. Vasc	ion, And Histochemica electively Recognizir erum Lipoproteins."	Application g Oxidatively
	Hansson GK, Libby P. (eds.). Immune Functions of the Vessel Wall, Volume II (Harwood Academic Publishers 1996). Chapter 9: Witztum JL, Palinski W. "Autoimmunity To Oxidized Lipoproteins." Pages 159-171.		96). Chapter
	Havel RJ, Eder HA, Bragdon JH. "The Distribution And Chemical Composition Of Ultracentrifugally Separated Lipoproteins In Human Serum." J. Clin. Invest. 1955; 34: 1345-1353.		oproteins In
	Heery JM, Kozak M, Staffor: McIntyre TM, Prescott SM. Phospholipids With Platelel And Stimulates The Growth (J. Clin. Invest. 1995: 96:	"Oxidatively Modifie t-Activating Factor-I Of Smooth Muscle Cell	ed LDL Contains like Activity

Hirschfield GM, Pepys MB. "C-reactive protein and cardiovascular disease: new insights from an old molecule." J Med. 2003 Nov: 96(11): 793-807. Hlatky MA. "Evaluation Of Chest Pain In The Emergency Department." N. Eng. J. Med. 1997; 337(23): 1687-1689. Hoff HF, O'Neill J. "Lesion-Derived Low Density Lipoprotein And Oxidized Low Density Lipoprotein Share A Lability For Aggregation, Leading To Enhanced Macrophage Degradation." Arterioscler. Thromb. 1991; 11(5): 1209-1222. Hoff HF, O'Neill J, Chisolm III GM, Cole TB, Quehenberger O, Esterbauer H, Jurgens G. "Modification Of Low Density Lipoprotein With 4-Hydroxynonenal Induces Uptake By Macrophages." Arteriosclerosis 1989; 9(4): 538-549. EXAMINER /Christine Foster/ (06/10/2009) DATE CONSIDERED 06/10/2009 Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and

not considered. Include copy of this form with next communication to applicant.

ceipt date:	02/12/2004	1	03FFEF58488 +8GAU: 1
Form PTO-1449 (Rev.)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. C015043/0174944	SERIAL NO. No Yet Assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Harold M. Bates	
(Use several sheets if necessary)		FILING DATE Filed Concurrently Herewith	GROUP Not Yet Assigned
	OTHER DOCUMENTS (Including A	uthor, Title, Date, Pertinent Pages, Etc.)	•
	Hoffmeister HM, Jur M, Wend "Alterations Of Coagulation Kinin Systems In The Acute With Unstable Angina Pector 2520-2527.	n And Fibrinolytic Ar And Post-Acute Phase	nd Kallikrein- es In Patients
	Holvoet P, Perez G, Bernar M, Collen D. "Stimulation Of Scavenger Receptor-Medi Low Density Lipoproteins By Foam Cell Generation." J.	With A Monoclonal Ar ated Uptake Of Chemic y THP-1-Derived Macro	ntibody (mAb4E4) cally Modified ophages Enhances
	Holvoet P, Collen D. "Betz To LDL Hypercholesterolemia Of Oxidized Lipoproteins Ar Coronary Atherosclerosis II Vasc. Biol. 1997; 17(11): 2	a Is Associated With nd A More Rapid Progn n Rabbits." Arterios	Higher Levels ression Of
	Holvoet P, Collen D. "Oxio		

Holvoet P, Collen D. "Thrombosis And Atherosclerosis." Opinion Lipidol. 1997; 8: 320-328. Holvoet P, Perez G, Zhao Z, Brouwers E, Bernar H, Collen D. "Malondialdehyde-Modified Low Density Lipoproteins In Patients With Atherosclerotic Disease." J. Clin. Invest. 1995; 95: 2611-2619. Holvoet P, Donck J, Landeloos M, Brouwers E, Luijtens K, Arnout J, Lesaffre E, Vanrenterghem Y, Collen D. "Correlation Between Oxidized Low Density Lipoproteins And Von Willebrand Factor In Chronic Renal Failure." Thromb. Haemost. 1996; 76(5): 663-669. Holvoet P, Van Kleemput J, Collen D, Vanhaecke J. "Correlation Between Oxidized Low Density Lipoproteins And Coronary Artery Disease In Heart Transplant Patients." Abstract published in Final Programme of 66th Congress of the European Atherosclerosis Society, Florence (Italy), July 13-14, 1996; Abstract Book, page 47.

EXAMINER DATE CONSIDERED

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and

(Christine Foster/ (06/10/2009)

not considered. Include copy of this form with next communication to applicant.

06/10/2009

ceipt date:	02/12/2004	10	0777543 - GAU: 1
Form PTO-1449 (Rev.)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. C015043/0174944	SERIAL NO. No Yet Assigned
INFOR	MATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Harold M. Bates	L
	(Use several sheets if necessary)	FILING DATE Filed Concurrently Herewith	GROUP Not Yet Assigned
	OTHER DOCUMENTS (Including A	uthor, Title, Date, Pertinent Pages, Etc.)	
	Holvoet P, Stassen JM, Van "Oxidized Low Density Lipo Transplant-Associated Coror Thromb. Vasc. Biol. 1998; 1	oproteins In Patients nary Artery Disease."	With
	Holvoet P, Theilmeier G, St *LDL Hypercholesterolemia I Oxidized LDL, Atherosclerot Vessel Enlargement In Coror Arterioscler. Thromb. Vasc.	Is Associated With Actic Plaque Growth, Annary Arteries Of Mini	cumulation Of d Compensatory ature Pigs."
	Holvoet P, Collen D, Vanhae Scientific Session Of The F Florida, November 9-12, and Circulation 1997; 96(Suppl.	American Heart Associ 1 published in abstra	ation, Orlando ct form in
	Holvoet P, Vanhaecke J, Jar "Oxidized LDL And Malondial With Acute Coronary Syndron Disease." Circulation 1999	ldehyde-Modified LDL nes And Stable Corona	In Patients

Assoc. 1999; 281(18): 1718-1721. "Oxidative Modification Of Low-Density Lipoproteins In Atherothrombosis." Acta Cardiol. 1998; 53(5): 253-260.

Holvoet P, Collen D, Van de Werf F. "Malondialdehyde-Modified LDL As A Marker Of Acute Coronary Syndromes." J. Am. Med.

Holvoet P. Mertens A. Verhamme P. Bogaerts K. Bevens G. Verhaeghe R, Collen D, Muls E, Van de Werf F. "Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease." Arterioscler Thromb Vasc Biol. 2001 May; 21(5): 844-848.

Holvoet P, Harris TB, Tracy RP, Verhamme P, Newman AB, Rubin SM, Simonsick EM, Colbert LH, Kritchevsky SB. "Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly: findings from the Health, Aging, and Body Composition study." Arterioscler Thromb Vasc Biol. 2003 Aug; 23(8): 1444-1448.

EXAMINER DATE CONSIDERED 06/10/2009 /Christine Foster/ (06/10/2009)

Form PTO-1449 (Rev.)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	SHEET 10 OF 18.
(Nev.)	FATERI AND INADEMARK OFFICE	C015043/0174944	No Yet Assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Harold M. Bates	
(Use se	everal sheets if necessary)	FILING DATE Filed Concurrently Herewith	GROUP Not Yet Assigned

OTHER DOCUMENTS (Including Author Title Date Pertinent Pages Fig.

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
Hruban RH, Beschorner WE, Baumbgartner WA, Augustine SM, Re H, Reitz BA, Hutchins GM. "Accelerated Arteriosclerosis In Heart Transplant Recipients Is Associated With A T-Lymphocyte-Mediated Endothelialitis." Am. J. Pathol. 1990; 137(4): 871-882.	
Hulthe J, Fagerberg B. "Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR Study)." Arterioscler Thromb V Biol. 2002 Jul 1; 22(7):1162-1167.	
Itabe H, Takeshima E, Iwasaki H, Kimura J, Yoshida Y, Imana T, Takano T. "A Monoclonal Antibody Against Oxidized Lipoprotein Recognizes Foam Cells In Atherosclerotic Lesion Complex Formation of Oxidized Phosphatidylcholines And Polypeptides." J. Biol. Chem. 1994; 269(21): 15274-15279.	
Itabe H, Yamamoto H, Imanaka T, Shimamura K, Uchiyama H, Kimura J, Sanaka T, Hata Y, Takano T. "Sensitive Detection Oxidatively Modified Low Density Lipoprotein Using A Monoclonal Antibody." J. Lipid Res. 1996; 37: 45-53.	Of
Juckett MB, Balla J, Balla G, Jessurun J, Jacob HS, Vercellotti GM. "Ferritin Protects Endothelial Cells From Oxidized Low Density Lipoprotein In Vitro." Am. J. Pathol. 1995; 147(3): 782-789.	
Kaplan R, Aynedjian HS, Schlondorff D, Bank N. "Renal Vasoconstriction Caused By Short-Term Cholesterol Feeding I Corrected By Thromboxane Antagonist Or Probucol." J. Clin. Invest. 1990; 86: 1707-1714.	s
Keane WF, Mulcahy WS, Kasiske BL, Kim Y, O'Donnell MP. "Hyperlipidemia And Progressive Renal Disease." Kidney Int 1991; 39(Suppl.): S41-S48.	
Kolata, G. "A New Generation Of Tests To Determine Heart Trouble." New York Times News Service. 7 pages (Nov. 26, 1995).	
EXAMINER /Christine Foster/ (06/10/2009) DATE CONSIDERED 06/10/2009	
Examinar Initial Chiration considered whether a not station is in another unit MICE CO. Down line hands sixting for the Co.	

Form PTO-1449	1449 U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	SERIAL NO.
(Rev.)	PATENT AND TRADEMARK OFFICE	C015043/0174944	NotYet Assigned
INFORM	IATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Harold M. Bates	<u> </u>
	(Use several sheets if necessary)	FILING DATE	GROUP
		Filed Concurrently Herewith	Not Yet Assigned
	OTHER DOCUMENTS (Including A	uthor, Title, Date, Pertinent Pages, Etc.)	
	Koskinen P, Lemstrom K, Br P. "Acute Cytomegalovirus Inflammation (Endothelialit A Possible Linkage With Er Am. J. Pathol. 1994; 144(1	Infection Induces A cis) In The Allograft chanced Allograft Art	Subendothelial Vascular Wall
	Kotani K, Maekawa M, Kanno "Distribution Of Immunoread Density Lipoprotein In Huma Acta 1994; 1215: 121-125.	ctive Malondialdehyde	-Modified Low-
	Lee TH, Goldman L. "Serum Myocardial Infarction, Anna 221-223.		
	Libby P, Salomon RN, Payne "Functions Of Vascular Wall Transplantation-Associated	l Cells Related To De	velopment Of

	A Possible Linkage With Enhanced Allograft Arteriosclerosis." Am. J. Pathol. 1994; 144(1): 41-50.
	Kotani K, Maekawa M, Kanno T, Kondo A, Toda N, Manabe M. "Distribution Of Immunoreactive Malondialdehyde-Modified Low-Density Lipoprotein In Human Serum." Biochimica et Biophysica Acta 1994; 1215: 121-125.
	Lee TH, Goldman L. "Serum Enzymes In The Diagnosis Of Acute Myocardial Infarction, Annals of Internal Medicine 1986; 105: 221-223.
	Libby P, Salomon RN, Payne DD, Schoen FJ, Pober JS. "Functions Of Vascular Wall Cells Related To Development Of Transplantation-Associated Coronary Arteriosclerosis." Transplant. Proc. 1989; 21(4): 3677-3684.
	Lynch SM, Morrow JD, Roberts II LJ, Frei B. "Formation Of Non-Cyclooxygenase-Derived Prostanoids (F2-Isoprostanes) In Plasma And Low Density Lipoprotein Exposed To Oxidative Stress In Vitro." J. Clin. Invest. 1994; 93: 998-1004.
	Mabile L, Fitoussi G, Periquet B, Schmitt A, Salvayre R, Negre-Salvayre A. "Alpha-Tocopherol And Trolox Block The Early Intracellular Events (TBARS And Calcium Rises) Elicited By Oxidized Low Density Lipoproteins In Cultured Endothelial Cells." Free Radic. Biol. Med. 1995; 19(2): 177-187.
	Major AS, Dove DE, Ishiguro H, Su YR, Brown AM, Liu L, Carter KJ, Linton MF, Fazio S. "Increased Cholesterol Efflux In Apolipprotein AI (ApoAI) -Producing Macrophages As A Mechanism For Reduced Atherosclerosis In ApoAI((-/-)) mice." Arterioscler Thromb Vasc Biol. 2001 Nov; 21(11): 1790-1795.
	Menschikowski M, Kasper M, Lattke P, Schiering A, Schiefer S, Stockinger H, Jaross W. "Secretory Group II Phospholipase A2 In Human Atherosclerotic Plaques." Atherosclerosis 1995; 118: 173-181.
EXAMINER	/Christine Foster/ (06/10/2009) DATE CONSIDERED 06/10/2009

Receipt date: 02/	12/2004		107777543F-16AU: 16
Form PTO-1449 (Rev.)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. C015043/0174944	SERIAL NO. No Yet Assigned
INFORMATI	ON DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Harold M. Bates	
(U:	se several sheets if necessary)	FILING DATE Filed Concurrently Herewith	GROUP Not Yet Assigned

OTHER DOCUMENTS (Including A	author, Title, Date, Pertinent Pages, Etc.)
	hology Of Homocysteine. I. Lab. Sci. 1993; 23(6): 477-493.
Cycloogenase-Derived Prost	J, Blair IA, Roberts II LJ. "Non- anoids (F2-isoprostanes) Are Formed Proc. Natl. Acad. Sci. USA 1992;
G et al. Letters and repl	et al., Oltrona L et al., and Liuzzo y by authors. "C-Reactive Protein n In Unstable Angina." N. Engl. J.
	ox PL. "Oxidized Low Density igration Of Aortic Endothelial Cells 1993; 120(4): 1011-1019.
	RF, Baum M, Baez A, Gupta S, Amarga Years Of Hemodialysis." Am. J.
Hamm CW, O'Hanesian MA, Wa Califf RM, Topol EJ. "Car	ristenson RH, Granger CB, Katus HA, gner GS, Kleiman NS, Harrell Jr. FE, diac Troponin T Levels For Risk ocardial Ischemia." N. Eng. J. Med.
O'Marcaigh AS, Jacobson RM Of A Diagnostic Test. How Results." Clin. Ped. 1993	. "Estimating The Predictive Value To Prevent Misleading Or Confusing ; 32(8): 485-491.
SS, Butler SW, Parthasarat JL. "Low Density Lipoprot	Ylä-Herttuala S, Gurtner GC, Socher hy S, Carew TE, Steinberg D, Witztum ein Undergoes Oxidative Modification d. Sci. USA 1989; 86: 1372-1376.
SA, Parthasarathy S, Curti	
/Christine Foster/ (06/10/2009)	DATE CONSIDERED 06/10/2009

 Receipt date: 02/1	2/2004	1)\$97€\$5\$39°- \GAU: 16
Form PTO-1449 (Rev.)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. C015043/0174944	SERIAL NO. NoTYet Assigned
INFORMATI	ON DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Harold M. Bates	
(Us	e several sheets if necessary)	FILING DATE Filed Concurrently Herewith	GROUP Not Yet Assigned
	OTHER DOCUMENTS (Including A	uthor, Title, Date, Pertinent Pages, Etc.)	
Ei Le	arthasarathy S, Wieland E, ndothelial Cell Lipoxygena ow Density Lipoprotein." 1 046-1050.	ase In The Oxidative	Modification Of
Penn MS, Chisolm GM. "Oxidized lipoproteins, altered cell function and atherosclerosis." Atherosclerosis 1994;			

108(Suppl.): S21-S29. Pocock SJ. Clinical Trials. A Practical Approach. Chapter 14: "Further Aspects Of Data Analysis." Pages 211-233. Wiley & Sons. 1993. Rasmussen O, Thomsen C, Ingerslev J, Hermansen K. "Decrease Of Von Willebrand Factor Levels After A High-Monounsaturated Fat Diet In Non-Insulin-Dependent Diabetic Subjects." Metabolism 1994; 43(11): 1406-1409. Ravalli S, Marboe CC, D'Agati VD, Michler RE, Sigal E, Cannon PJ. "Immunohistochemical Demonstration Of 15-Lipoxygenase In Transplant Coronary Artery Disease." Arterioscler. Thromb. Vasc. Biol. 1995; 15(3): 340-348. Reade V, Tailleux A, Reade R, Harduin P, Cachera C, Tacquet A, Fruchart JC, Fievet C. "Expression Of Apolipoprotein B Epitopes In Low Density Lipoproteins Of Hemodialyzed Patients." Kidney Int. 1993; 44: 1360-1365. Reverter JC, Escolar G, Sanz C, Cases A, Villamor N, Nieuwenhuis HK, Lopez J, Ordinas A. "Platelet Activation During Hemodialysis Measured Through Exposure Of P-Selectin: Analysis By Flow Cytometric And Ultrastructural Techniques." J. Lab. Clin. Med. 1994; 124(1): 79-85. Ridker PM, Glynn, RJ, Hennekens, CH. "C-Reactive Protein Adds To The Predictive Value Of Total And HDL Cholesterol In Determining Risk Of First Myocardial Infarction." Circulation 1998; 97:2007-2011. EXAMINER DATE CONSIDERED /Christine Foster/ (06/10/2009) 06/10/2009

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and

not considered. Include copy of this form with next communication to applicant.

SHEET 14 OF 18

Receipt date: 02/12/2004

			0110011101
Form PTO-1449 (Rev.)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. C015043/0174944	SERIAL NO. No Yet Assigned
		C01504510174544	
INFORM	ATION DISCLOSURE STATEMENT	APPLICANT	
	BY APPLICANT	Harold M. Bates	
	(Use several sheets if necessary)	FILING DATE	GROUP
		Filed Concurrently Herewith	Not Yet Assigned
	OTHER DOCUMENTS (Including A	uthor, Title, Date, Pertinent Pages, Etc.)	
	Ridker PM, Buring JE, Shih "Prospective Study Of C-Rea Future Cardiovascular Event Circulation 1998; 98:731-73	active Protein And Th ts In Stable And Unst	e Risk Of
	Rose EA, Smith CR, Petrossian GA, Barr ML, Reemtsma K. "Humoral Immune Responses After Cardiac Transplantation: Correlation With Fatal Rejection And Graft Atherosclerosis." Surgery 1989; 106(2): 203-208.		
	Rosenfeld ME, Palinski W, "Distribution Of Oxidation Apolipoprotein B In Atheros Severity From WHHL Rabbits 336-349.	n Specific Lipid-Prot sclerotic Lesions Of	ein Adducts And Varying
	Ross R. "The Pathogenesis For The 1990s." Nature 199		A Perspective
	Salonen JT, Yla-Herttuala Salonen R, Nyyssonen K, Pa Against Oxidised LDL And Pr Atherosclerosis." Lancet	linski W, Witztum JL. rogression Of Carotic	"Autoantibody
	Sasavage N. "Predicting Co Could Identify Patients At pages 6-7.		
	Savenkova ML, Mueller DM, I Generated By Myeloperoxidas The Initiation Of Lipid Pel Lipoprotein." J. Biol. Ch	se Is A Physiological roxidation In Low Den	Catalyst For

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

/Christine Foster/ (06/10/2009)

EXAMINER

DATE CONSIDERED

06/10/2009

Schaffner T, Taylor K, Bartucci EJ, Fischer-Dzoga K, Beeson JH, Glagov S, Wissler RW. "Arterial Foam Cells With Distinctive Immunomorphologic And Histochemical Features Of Macrophages." Am. J. Pathol. 1980; 100(1): 57-80.

. .. . Receipt date: 02/12/2004 1035055430F (GAU: 1641 Form PTO-1449 U.S. DEPARTMENT OF COMMERCE ATTY, DOCKET NO. SERIAL NO (Rev.) PATENT AND TRADEMARK OFFICE NotYet Assigned C015043/0174944 APPLICANT INFORMATION DISCLOSURE STATEMENT BY APPLICANT Harold M. Bates (Use several sheets if necessary) FILING DATE GROUP Filed Concurrently Herewith Not Yet Assigned OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Schonbeck U, Gerdes N, Varo N, Reynolds RS, Horton DB, Bavendiek U, Robbie L, Ganz P, Kinlay S, Libby P. Low-Density Lipoprotein Augments And 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Limit CD40 And CD401 Expression In Human Vascular Cells." Circulation 2002; 106(23): 2888-2893. "Quantification And Significance Of Protein Oxidation In Biological Samples." Drug Metab Rev. 2000 Aug-Nov; 32(3-4): 307-26. Shultz EK. "Clinical Interpretation Of Laboratory Procedures." Chapter 14 in Teitz, Fundamentals of Clinical Chemistry. Burtis CA, Ashwood ER (eds.). 4th edition 1996. W.B. Saunders Company. Pages 192-199. Schulz T, Schiffl H, Scheithe R, Hrboticky N, Lorenz R. "Preserved Antioxidative Defense Of Lipoproteins In Renal

Failure And During Hemodialysis." Am. J. Kidney Dis. 1995; 25(4): 564-571. Selwyn AP, Kinlay S, Libby P, Ganz P. "Atherogenic Lipids. Vascular Dysfunction, And Clinical Signs Of Ischemic Heart Disease." Circulation 1997; 95(1): 5-7. Sparrow CP, Olszewski J. "Cellular Oxidative Modification Of Low Density Lipoprotein Does Not Require Lipoxygenases." Proc. Nat. Acad. Sci. USA 1992; 89: 128-131. Sparrow CP, Partharasathy S, Leake DS, Steinberg D. "Enzymatic Modification Of Low Density Lipoprotein By Purified Lipoxygenase Plus Phospholipase-A2 Mimic Cell-Mediated Oxidative Modification." J. Lipid Res. 1988; 29: 745-753. Steinberg D, Witztum JL. "Lipoproteins And Atherogenesis: Current Concepts." J. Am. Med. Assoc. 1990; 264(23): 3047-3052. FXAMINER /Christine Foster/ (06/10/2009) DATE CONSIDERED 06/10/2009

eceipt date: 02/12/2004			1039555430F (SAU: 16
	ARTMENT OF COMMERCE	ATTY. DOCKET NO.	SERIAL NO.
	AND TRADEMARK OFFICE	C015043/0174944	No Yet Assigned
INFORMATION DISCLOSURE STATEMENT		APPLICANT	
BY APPLICANT		Harold M. Bates	
(Use several sheets if no	cessary)	FILING DATE Filed Concurrently Herewith	GROUP Not Yet Assigned

Steinberg D. "Clinical T Atherosclerosis: Are We D 346: 36-38.	rials Of Antioxidants In ping The Right Thing?" Lancet 1995;
Steinberg D. "Lewis A. C Modification Of LDL And A 1062-1071.	onner Memorial Lecture. Oxidative therogenesis." Circulation 1997; 95:
Steinberg D. "Modificati Endothelial Cells Involve	rathy S, Leake DS, Witztum JL, on Of Low Density Lipoprotein By s Lipid Peroxidation And Degradation n Phospholipids." Proc. Nat. Acad. 887.
Results In Derivatization	ion Of Low Density Lipoprotein Of Lysine Residues Of Apolipoproteir position Products." J. Biol. Chem.
Stimulation Of Cholestero	M. "Scavenger Receptor-Independent 1 Esterification In Macrophages By ktracted From Human Aortic Intima." 2; 12(5): 608-625.
"Oxidation Of Low Density	Ball MJ, Stapley SA, Robertson MC. Lipoproteins From Patients With ansplants." Kidney Int. 1995; 48:
"Single LDL Apheresis Imp	e H, Wada Y, Kohno K, Imaizumi T. coves Endothelium-Dependent esterolemic Humans." Circulation
Libby P. "Endothelial An Leukocyte Adhesion Molecu	nson SJ, Cybulsky MI, Schoen FJ, i Smooth Muscle Cells Express les Heterogeneously During Acute ac Allografts." Am. J. Pathol. 1994;
CAMINER /Christine Foster/ (06/10/2009)	DATE CONSIDERED 06/10/2009

Form PTO-1449 (Rev.)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. C015043/0174944	SERIAL NO. No Yet Assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT Harold M. Bates	
		FILING DATE Filed Concurrently Herewith	GROUP Not Yet Assigned
	OTHER DOCUMENTS (Including A	uthor, Title, Date, Pertinent Pages, Etc.)
	Trachtman H, Schwob N, Maes Vitamin E Supplementation / Puromycin Aminonucleoside I 1995; 5(10): 1811-1819.	Ameliorates Renal I	njury In Chronic

	Vitamin E Supplementation Ar	aka J, Valderrama E. "Dietary meliorates Renal Injury In Chronic ephropathy." J. Am. Soc. Nephrol.	
	Robinson K, McCarthy PM, Ste "Occult And Frequent Transm Disease With Cardiac Transp	G, Bott-Silverman C, De Franco AC, ewart RW, Guyer S, Nissen SE. Ission Of Atherosclerotic Coronary Lantation. Insights From Circulation 1995; 91(6): 1706-1713.	
	Y, Suzuki D, Miyata T, Nogue	i K, Matsuda T, Hattori N, Mizuno chi N, Niki E, Osawa T. "Protein- arkers For Oxidative Stress." 1998; 95: 4882-4887.	
	Van de Werf F. "Cardiac Tro Syndromes." N. Eng. J. Med	oponins In Acute Coronary . 1996; 335(18): 1388-1389.	
	Varo N, de Lemos JA, Libby P, Morrow DA, Murphy SA, Nuzzo R, Gibson CM, Cannon CP, Braunwald E, Schonbeck U. "Soluble CD40L: Risk Prediction After Acute Coronary Syndromes." Circulation 2003; 108(9): 1049-1052.		
	Dilley RB, DeLaria GA, Saver Eschenmoser A, Lerner RA.	xeuchi C, Galve R, Wentworth AD, n A, Babior BM, Janda KD, "Evidence for ozone formation in ies." Science 2003; 302(5647):	
	Ylä-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL, Steinberg D. "Evidence For The Presence Of Oxidatively Modified Low Density Lipoprotein In Atherosclerotic Lesions Of Rabbit And Man." J. Clin. Invest. 1989 October; 84: 1086-1095.		
		AM, Murti CRK. "A Rapid Method For com Frog Leg Skeletal Muscle." e 7; 96(23): 196091e.	
EXAMINER	/Christine Foster/ (06/10/2009) D	ATE CONSIDERED 06/10/2009	
Evaminer: Initial if	citation considered, whether or not citation is in conformance	with MDED 600. Draw line through citation if not in conformance and	

Form PTO-1449 (Rev.)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. C015043/0174944	SERIAL NO. No Yet Assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT Harold M. Bates	
		FILING DATE	GROUP
		Filed Concurrently Herewith	Not Yet Assigned
	OTHER DOCUMENTS (Including A	uthor, Title, Date, Pertinent Pages, Etc.)	
	Zawadzki Z, Milne RW, Marce Low Density Lipoprotein Oxi 885-891.		
	Zhao B, Dierichs R, Harrach "Oxidized LDL Induces Serot Am. J. Hematol. 1995; 48:	onin Release From E	
	Zwaginga JJ, Koomans HA, Si Formation And Platelet-Vess Nephrotic Syndrome Under Fl	sel Wall Interaction	n In The

1994; 93: 204-211. Zweig MH, Broste SK, Reinhart RA. "ROC Curve Analysis: An Example Showing The Relationships Among Serum Lipid And Apolipoprotein Concentrations In Identifying Patients With Coronory Artery Disease." Clin. Chem. 1992; 38(8): 1425-1428. EXAMINER DATE CONSIDERED 06/10/2009 /Christine Foster/ (06/10/2009)